facebook tracking

NPPA

NPPA Imposes 30% Trade Margin Cap on 137 Non-Scheduled Anti-Cancer Drugs


regulatory illustration
Importer & Manufacturer   |   Source: NPPA
Published On: 17-10-2026

Enforcement Date: 17 October, 2026
NPPA Imposes 30% Trade Margin Cap on 137 Non-Scheduled Anti-Cancer Drugs

The National Pharmaceutical Pricing Authority (NPPA) has invoked Paragraph 19 of the Drugs (Prices Control) Order, 2013, to impose a maximum trade margin of 30% on non-scheduled formulations containing 137 specified anti-cancer drugs. Manufacturers must recalculate MRPs using the prescribed formula based on March 2026 Price to Stockist/Price to Distributor (PTS/PTD) data. The revised prices will take effect from 9 November 2026.


The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, has issued an order invoking Paragraph 19 of the Drugs (Prices Control) Order, 2013, to rationalise trade margins and improve the affordability of non-scheduled anti-cancer drugs. The order covers 137 specified non-scheduled anti-cancer drugs, including patented drugs, whether marketed individually or in combinations and irrespective of strength, dosage form or route of administration.


Key points include:

  1. A maximum 30% trade margin cap has been imposed on covered formulations.
  2. Manufacturers must calculate the revised MRP using the prescribed formula based on the March 2026 PTS/PTD, plus applicable GST.
  3. The revised prices will come into effect from 9 November 2026.
  4. Manufacturers must submit revised price information in Annexure I within 7 days of publication and report the information to NPPA and the concerned State Drug Controller.
  5. MRPs exceeding the calculated limit must be reduced, while manufacturers whose existing MRPs are lower must maintain them.
  6. Patient Assistance Programme (PAP) quantities may be excluded from the calculation subject to specified conditions, including free supply and record maintenance.
  7. Manufacturers must maintain existing production levels and obtain prior NPPA permission before reducing average monthly production. Discontinuation requires at least six months' prior intimation.
  8. Non-compliance may result in recovery of overcharged amounts with interest.

Applicable For: Importer & Manufacturer
Reference Number: CG-DL-E-17102026-277271 Notification Link

Related Regulatory Updates

Contact us

Please feel free to talk to us if you have any questions. We endeavour to answer within 24 hours.